LivaNova PLC LIVN
LivaNova PLC is a market-leading global medical technology company. The Company designs, develops, manufactures, markets, and sells products, therapies, and services that are consistent with LivaNova's mission to "create ingenious medical solutions that ignite patient turnarounds." LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England. LivaNova's ordinary shares are listed for trading on the Nasdaq under the symbol "LIVN."
LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop and execute its strategy, and assess performance. LivaNova has two reportable segments: Cardiopulmonary and Neuromodulation. "Other" includes non-allocated corporate expenses and the non-cannula results of the Company's former ACS segment, which was wound down during 2024.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.39B | $1.25B | $1.15B | $1.02B | $1.04B | $934.2M | $1.08B | $1.11B | $1.01B | $964.9M |
| Cost of revenue | $448.2M | $400.0M | $397.7M | $314.6M | $329.4M | $339.5M | $360.4M | $361.3M | $353.2M | $367.8M |
| Gross profit | $939.9M | $853.5M | $755.8M | $707.2M | $706.0M | $594.8M | $723.8M | $745.6M | $651.6M | $559.5M |
| R&D | $185.8M | $182.5M | $193.8M | $155.8M | $183.4M | $152.9M | $146.8M | $145.9M | $109.5M | $82.1M |
| SG&A | $548.8M | $508.9M | $502.7M | $469.2M | $471.9M | $446.6M | $528.5M | $465.0M | $380.1M | $355.2M |
| Total operating expenses | — | — | — | — | — | — | — | — | $556.0M | $528.1M |
| Operating income | $199.4M | $129.1M | -$68.5M | -$76.8M | -$784.0K | -$273.9M | -$171.6M | -$248.1M | $96.5M | $33.4M |
| Interest expense | $49.3M | $63.1M | $58.9M | $48.2M | $50.2M | $40.8M | $15.1M | $9.8M | $7.8M | $10.6M |
| Pre-tax income | -$220.8M | $88.3M | -$81.2M | -$75.1M | -$124.5M | -$348.0M | -$188.4M | -$247.4M | $121.1M | $25.7M |
| Income tax | $21.6M | $25.1M | $98.9M | $11.1M | $11.2M | $960.0K | $30.4M | $69.6M | $50.0M | $5.1M |
| Net income | -$242.5M | $63.2M | $17.6M | -$86.2M | -$135.8M | -$348.8M | -$157.6M | -$189.4M | -$25.1M | -$62.8M |
| EPS, basic | -4.45 | 1.17 | 0.33 | -1.61 | -2.68 | -7.18 | -3.21 | -3.91 | -0.52 | -1.29 |
| EPS, diluted | -4.45 | 1.16 | 0.32 | -1.61 | -2.68 | -7.18 | -3.26 | -3.91 | -0.52 | -1.28 |
| Shares, diluted (wtd. avg.) | $54.5M | $54.6M | $54.2M | $53.5M | $50.6M | $48.6M | $48.3M | $48.5M | $48.5M | $49.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $635.6M | $428.9M | $266.5M | $515.6M | $208.0M | $252.8M | $61.1M | $47.2M | $93.6M | $39.8M |
| Receivables | $216.0M | $193.2M | $215.1M | $183.1M | $185.4M | $184.4M | $257.8M | $256.1M | $282.1M | $213.3M |
| Inventory | $164.7M | $147.6M | $147.9M | $129.4M | $105.8M | $115.3M | $164.2M | $153.5M | $144.5M | $133.0M |
| Total current assets | $1.10B | $1.13B | $988.2M | $886.1M | $679.2M | $708.0M | $549.4M | $533.3M | $869.9M | $812.7M |
| Property, plant and equipment | $242.6M | $170.3M | $154.2M | $147.2M | $150.1M | $163.8M | $181.4M | $191.4M | $192.4M | $203.7M |
| Goodwill | $792.8M | $750.0M | $782.9M | $768.8M | $899.5M | $922.3M | $915.8M | $956.8M | $784.2M | $691.7M |
| Other intangibles | $230.0M | $237.3M | $261.2M | $368.6M | $399.7M | $437.6M | $607.5M | $770.4M | $446.4M | $609.2M |
| Total assets | $2.61B | $2.51B | $2.43B | $2.29B | $2.20B | $2.40B | $2.41B | $2.55B | $2.50B | $2.34B |
| Accounts payable | $97.2M | $69.7M | $80.8M | $74.3M | $68.0M | $73.7M | $85.9M | $76.7M | $85.9M | $71.9M |
| Short-term debt | $30.9M | $77.3M | $17.5M | $20.9M | $226.9M | $8.4M | $73.2M | $23.3M | $25.8M | $21.3M |
| Total current liabilities | $808.1M | $392.1M | $335.0M | $297.4M | $697.0M | $309.1M | $512.6M | $496.7M | $406.0M | $349.9M |
| Long-term debt | $345.2M | $549.6M | $568.5M | $518.1M | $9.8M | $642.3M | $260.3M | $139.5M | $62.0M | $75.2M |
| Total liabilities | $1.41B | $1.19B | $1.15B | $1.09B | $906.3M | $1.29B | $1.03B | $1.05B | $688.6M | $635.7M |
| Retained earnings | -$1.15B | -$903.2M | -$966.5M | -$984.0M | -$897.8M | -$762.0M | -$406.8M | -$251.6M | -$39.7M | -$14.6M |
| Total equity | $1.20B | $1.32B | $1.28B | $1.21B | $1.29B | $1.11B | $1.38B | $1.50B | $1.82B | $1.71B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $254.3M | $183.0M | $74.9M | $69.9M | $102.5M | -$79.4M | -$91.1M | $120.5M | $91.3M | $90.2M |
| Depreciation and amortisation | $28.6M | $25.1M | $24.7M | $22.4M | $24.5M | $29.0M | $30.3M | $32.7M | $37.1M | $39.9M |
| Stock-based compensation | $36.3M | $33.9M | $36.4M | $44.8M | $40.6M | $35.1M | $32.6M | $26.9M | $19.1M | $19.6M |
| Capital expenditure | $81.0M | $47.1M | $35.0M | $26.5M | $25.5M | $35.0M | $24.7M | $37.2M | $32.9M | $38.4M |
| Investing cash flow | -$72.9M | -$48.2M | -$40.3M | -$38.4M | $36.9M | -$41.8M | -$41.3M | -$120.6M | -$52.9M | -$44.5M |
| Financing cash flow | -$285.7M | $18.6M | $21.5M | $280.1M | -$181.5M | $310.8M | $146.6M | -$42.3M | $11.3M | -$118.0M |
| Buybacks | — | — | — | — | — | $0 | $0 | $50.0M | $0 | $54.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-050937.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $120.46B | 25.2x | 8.4% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $3.12B | 18.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.60B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.72B | — | 28.9% |
| CNMD | CONMED Corp | $1.48B | 32.7x | 5.2% |
| CBLL | Ceribell, Inc. | $948.7M | — | 36.1% |
| CV | CapsoVision, Inc | $299.8M | — | 15.3% |